You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

Welcome to the 2-Drug Regimen Era

A 20-year-old starting a 3-drug regimen may be on therapy for nearly 6 decades, which translates to more than 60,000 doses of individual medications.  No one should take more medicines than they need.

Read More

Fast Facts Infographic

Read a summary of DTG + 3TC in
                    this Fast Facts Infographic

Patient Information Booklet

Answers FAQs for patients who have been prescribed DTG + 3TC

*For further details please see the Tivicay and Epivir (lamivudine) SPCs available from

Tivicay + lamivudine is only suitable for the treatment of HIV-1 infection where there is no known or suspected resistance to the integrase inhibitor class, or to lamivudine.

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions.

Trademarks are owned by or licensed to the ViiV Healthcare group of companies.